Project Grant R37CA306827
Award Date 9/15/25
Completion Date 8/31/30
Dollars Obligated $688K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27599, USA
Similar Awards
- This $165,012 Project Grant, awarded by the National Institute on Minority Health and Health Disparities (NIMHD) under the Minority Health and Health Disparities Research (CFDA 93.307) program, supports the development and feasibility testing of a multi-level, community-engaged intervention to increase access to cervical cancer screening using HPV self-collection (HPVSC) outreach among high-risk, rural women in North Carolina. The project aims to: 1) establish a Community Advisory Board (CAB) to...
- This $544,250 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of Nebraska Medical Center (UNMC) will support research to investigate the immune drivers of persistent oncogenic infections, such as oral human papillomavirus (HPV), and their progression to cancer among people living with HIV. The overarching goal is to improve prevention, early detection, and treatment outcomes for infection-related cancers in this high-risk...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $630,506 to The Johns Hopkins University to develop and test a therapeutic vaccine against cervical cancer associated with variants of the human papillomavirus type 16 (HPV16). The primary goals are to: 1) characterize how different HPV16 variants evade immune system detection, 2) study the growth and tumor microenvironment of spontaneous cervical/vaginal cancers driven by HPV16...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $544,768 to the University of New Mexico to conduct research focused on understanding the fundamental biological mechanisms of human papillomavirus (HPV)-induced tumors and precancerous lesions. The award aims to elucidate how inhibition of the MEK/ERK signaling pathway can lead to regression of HPV-driven tumors, with the goal of advancing scientific knowledge that can enable improved...
- This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $442,750.00 to New York University (NYU) to conduct a study on implementation strategies for cervical cancer control policies in Africa. The project aims to: (A) Engage a network of experts from African low- and middle-income countries (LMICs) and global agencies through a Delphi process to identify determinants of policy implementation success, using the Consolidated...
- The University of North Carolina at Chapel Hill (UNC-CH) received a $514,582 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct research on "Targeting APOBEC3-Induced Squamous Differentiation in Bladder Cancer". The award began on March 1, 2025 and is set to conclude on February 28, 2030. The research aims to investigate the role of APOBEC3 enzymes in bladder cancer initiation and progression,...
- This Project Grant, awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), provides $627,148.00 to the University of Maryland, College Park to develop an injectable, low-cost ablative therapy based on ethyl cellulose-ethanol gel for treating cervical dysplasia. The goal is to create an alternative to current costly and technically complex cervical cancer prevention solutions that are not practical for use in medically underserved regions. The project...
- The University of Texas Health Science Center at Houston (UTHealth) received a $170,409 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393). The grant supports a study examining the prevalence of human papillomavirus (HPV) and HPV-related cancer prevention behaviors among people experiencing homelessness in the United States from 2006 to 2018. The study aims to establish a baseline understanding of HPV burden and...
- The National Cancer Institute (NCI) awarded a $202,487 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to evaluate the adoption, implementation, and maintenance of thermal ablation, a cervical precancer treatment, in El Salvador. The project aims to investigate how features common to low- and middle-income countries shape the outcomes of integrating this evidence-based...
- The National Cancer Institute (NCI) awarded a $753,446 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to Boston Medical Center Corporation (BMC) to develop and evaluate an intervention to improve cervical cancer screening and follow-up in underserved populations. The intervention, known as DOSE-CC, combines education and quality improvement methods to help clinicians enhance their cervical cancer prevention practices. The goal is to adapt BMC's prior...